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Introduction
The field of mechanical circulatory support is evolving rapidly and new data are
published at a rate which can be overwhelming. For the last three years, we
published annual reviews of the current literature entitled “What Did We Learn
about VADs?” in the past year (1-3). All three papers were well received as the full
texts were downloaded 704, 676 and 413 times, respectively, by the readers
around the globe. Continuing the tradition, we have written the present review and
as with all previous reviews, we summarized some publications from 2017 that we
think are of particular importance and interest. There may be some slight overlap
with the end of 2016 due to some papers having been published online first.
For the first time this year we added a section on extracorporeal membrane
oxygenation (ECMO), primarily addressing new developments in the veno-arterial
(VA) ECMO. We plan to make it a regular feature of these reviews.

Competing interests: Not applicable

The VAD Journal: https://doi.org/10.13023/VAD.2018.04

Page 1 of 28

The VAD Journal: The journal of mechanical assisted circulation and heart failure

Readers who wish to supplement this review or to argue with the author’s
statements or article selection are encouraged to do so by sending letters to the
editor or posting on our Facebook page at
https://www.facebook.com/TheVADJournal. Comments are welcome via the link
“Readers comments” on our homepage http://uknowledge.uky.edu/vad/.

HeartMate 3
In August 2017, HeartMate 3 (HM3) (Abbott, Abbott Park, IL) was approved by
Food and Drug Administration (FDA) as a bridge to transplantation. As we are
awaiting further results from the Multicenter Study of MagLev Technology in
Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate3
MOMENTUM 3), a randomized trial comparing HM3 and HM2 (Abbott, Abbott Park,
IL), new information about this pump has been accumulating.
The outcomes continue to be encouraging. In a single-center study, survival on
HM3 was 88.9% at 30 days and 85.2% at 6 months. During this time no strokes
were observed (4). Per previous reports, six month survival was 92%, with a 12%
stroke rate (5). In the MOMENTUM 3 survival without stroke or pump replacement
was 86.2%. Remarkably, no pump thrombosis or pump exchanges occurred in any
study (6) .
One-year outcomes have already been reported from the European HM3 study
and are consistent with 18% mortality, 18% strokes, and 2% outflow graft
thrombosis. There were no cases of pump thrombosis or pump malfunction (7) .
The 2% outflow graft thrombosis represents a single patient and was a true
thrombosis with embolization to the brain. This is worth explaining because there
was also a report of HM3 outflow graft stenosis by extraluminal thrombotic masses
accumulating between the bend relief and the outflow graft, which was diagnosed
by direct inspection during subsequent heart transplantation (8). Also, late postpump stenosis due to twisted outflow graft was reported (9). Finally, there was a
report of HM3 thrombosis triggered by a shock from an automatic implantable
cardioverter defibrillator, triggering the release of a left ventricular (LV) thrombus
which was sucked in the left ventricular assist device (LVAD) inflow cannula (10).
There is already an experience of exchanging older pumps, both HM2 and
HeartWare, to HM3 (11).
Hemocompatibility of HM3 was systematically studied in the MOMENTUM 3 trial,
where the freedom of the combination of nonsurgical bleeding, thromboembolic
events, pump thrombosis, or neurological events was 69% of the HM3 group and
55% of the HM2 group (hazard ratio (HR) 0.62; confidence intervals (CI) 0.420.91; P=0.012). Specifically, patients on HM3 had less pump thrombosis and
nondisabling strokes (12).

The VAD Journal: https://doi.org/10.13023/VAD.2018.04

Page 2 of 28

The VAD Journal: The journal of mechanical assisted circulation and heart failure

HeartWare
In October 2017 HeartWare (Medtronic, Minneapolis, MN) was approved by FDA
for destination therapy. This happened after the publication of the prospective,
randomized, controlled, un-blinded, multicenter clinical trial to Evaluate the
HeartWare Ventricular Assist System for Destination Therapy of Advanced Heart
Failure (ENDURANCE) comparing safety and effectiveness of the HeartWare
pump with HM2.
The Kaplan–Meier estimates of survival free from disabling stroke or need for
device replacement at 2 years, which was the study primary end point, were
55.0% for HeartWare and 57.4% for HM2 (not significant) and met the criteria for
non-inferiority. The Kaplan–Meier rate of overall survival at 2 years was 60.2% in
the HeartWare group and 67.6% in the HM2 group (P = 0.17). The rates of major
bleeding, cardiac arrhythmias, renal dysfunction, and infections, including
percutaneous drive-line infections were similar on both devices; however, there
were more strokes on HeartWare than on HeartMate II (29.7% vs. 12.1%,
P<0.001). On the other hand, more patients in the HM2 group than in the
Heartware group had device malfunction or required pump replacement (16.2% vs.
8.8%). Quality of life and functional capacity improved to a similar degree in the
two groups (13).
A post hoc analysis of HeartWare recipients revealed that mean arterial blood
pressure measurements of ≤90 mm Hg were associated with a lower frequency of
strokes, particularly hemorrhagic strokes.
Fortunately, the rate of adverse events on HeartWare decrease with time. The
analysis of the HeartWare Ventricular Assist Device for the Treatment
of Advanced Heart Failure (ADVANCE) Bridge to Transplant trial and continued
access protocol found that there were significantly fewer total adverse events after
first 30 days post implantation with the lowest rates after six months. For instance,
rates of hemorrhagic strokes decreased from 0.23 events per patient-year in the
first 30 days to 0.08 after 30 days and up to 6 months, 0.09 between 6 months and
one year, and 0.06 after the first year. Additionally, the corresponding decrease in
ischemic strokes was 0.36 to 0.05 after 30 days and remained unchanged
thereafter (14).
An excellent analysis of HeartWare waveforms was published by Rich and
Burkoff.(15) They presented changes in the morphology of waveforms in multiple
clinical scenarios including blood pressure changes (a low flow, high-pulsatility
waveform in hypertension versus high-flow, low-pulsatility waveform in relative
hypotension due to excessive vasodilatation), arrhythmia, abrupt or gradual pump
thrombosis, suction events, etc.
Importantly, it appears that HeartWare waveforms can be used for noninvasive
assessment of hemodynamics. As described by Grinstein et al.(16), the slope of
the ventricular filling phase on the HeartWare waveform correlates
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with pulmonary capillary wedge pressure (PCWP). Specifically, the slope was
significantly steeper in patients with the wedge pressure ≥ 18 mm Hg than in
patients with PCWP < 18 mm, and the slope threshold of 5.8 L/min/s predicted a
wedge pressure ≥ 18 mm Hg with a sensitivity of 87% and specificity of 95% (area
under curve 0.95).

Outcomes
According to the 8th annual INTERMACS report, overall survival while on LVAD
support continues to remain 81% at one year and 70% at 2 years. There is an
increasing proportion of implantations in lower risk profile 3, stable inotropedependent patients, which currently account for 38% of new implants. Analysis of
causes of death on LVAD support showed that in the first 6 months after surgery
patients die from multisystem organ failure, right ventricular (RV) failure, and
strokes (ischemic or hemorrhagic). After the first half a year stroke dominates as
the major cause of death. The biggest contributor to early mortality is the need for
right ventricular assist device at the original operation, with a hazard ratio of 3.76.
Patients who undergo surgery while being in cardiogenic shock have a two-fold or
greater propensity for severe RV failure comparing to more stable patients. On
total artificial heart support, one year survival remains less than 60% (17).
When the INTERMACS data were stratified by center volume the worst survival
was observed at very low volume centers, performing ≤10 implants a year, and the
best at medium volume with 30 to 50 LVAD implantations per year (18).
There was also a report of a single-center study with the data on 5-year survival of
patients on HM2, which was 54% (19).
Interesting analysis of adverse events on two different VADs, HM2 and
HeartWare, summarized the experience of several institutions and included
hundreds of patients. Overall mortality was similar (7.3% and 7.5%), as were the
rates of gastrointestinal (GI) bleeding (P =0.63), any infection (P =0.32), driveline
infection (P = 0.10), and pump thrombus (P =0.64). At the same time, HeartWare
was associated with higher risk of stroke (HR: 1.8, [1.25, 2.5], P = 0.003). Because
of a major manufacturing change in the sintering of the HeartWare in August 2011,
authors analyzed cumulative incidence of stroke for patients who were implanted
with the HeartWare before and after this change, which was 36% and 28%,
respectively, the difference not being significant (20).

Recovery
In terms of myocardial recovery on LVAD support, there was more skepticism than
optimism in 2017. Farris et al. (21) studied the samples of cardiac muscle before
and after several months of support on LVAD and found no difference in capillary
density, cardiac fibrosis, or macrophage density. On the other hand, there was a
very significant, almost 17-fold, decrease in fibroblast-specific collagen
expression. This shows that despite the normal appearance of the ventricle,
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achieved with mechanical unloading, there is persistent abnormal gene
expression. Reversal of the geometric alternations by mechanical unloading does
not equate to reversal of the cellular and transcriptional machinery to normal, as
stated in the editorial suggesting that recovery may be an illusion (22). The same
editorial introduces the term “heart failure remission” rather than recovery.

Candidate selection
The ROADMAP (Risk Assessment and Comparative Effectiveness of Left
Ventricular Assist Device and Medical Management) was a prospective,
multicenter observational study of 200 patients (97 LVAD, 103 medical
management) who had at least one hospitalization for heart failure (HF) in the last
year and walked less than 300 m on 6-min walk, i.e. were functionally limited but
not inotrope-dependent. They can be managed by either medical therapy or LVAD
based on subjective factors. Although patients who opted for LVAD were sicker at
baseline, the primary endpoint, survival with improvement in 6 minute walk
distance by more than 75 m at 12 months, was achieved by 39% patients on
LVADs versus 21% on medical management (OR 2.4, p = 0.012). Survival per se
was also greater for LVAD versus medical management (80 ± 4% vs. 63 ± 5%; p =
0.022). Even despite more hospitalizations on LVADs, mostly for GI bleedings,
quality of life improved greater than in the medical arm (23). In 2017, two-year
outcomes of the ROADMAP were published (24). They were very consistent with
the one-year outcomes of 30% patients on LVAD versus 12% on medical
management survived with improved functional status (odds ratio: 3.2 [95% CI: 1.3
to 7.7]; p = 0.012). Survival as treated on original therapy at 2 years was greater
70 ± 5% for LVAD versus 41 ± 5% for medical management, p < 0.001. In the
medical arm, 22% received delayed LVADs. Also, LVAD-related complications
declined after one year on support (24).
Shah et al.(25) stratified the ROADMAP population by INTERMACS profile and
demonstrated that patients who benefited from LVADs, in terms of both survival
and functional status, had profile 4 (“resting symptoms on oral therapy”), while in
profiles 5,6I, and 7 (“exertion intolerant/exertion limited/tolerates minimal exertion”)
medical management may be sufficient.
Basically, this study means that many INTERMACS class 4 patients, or the first
class of patients who are not inotrope dependent, can benefit from LVAD support.
Frailty
Frailty before destination LVAD implantation is associated with increased risk of
death (26), however in 50% to 90% of patients, frailty at least partially reverses in
six months on LVAD support (27, 28). Caution is needed before denying LVAD
implant due to frailty.
Pulmonary function
Most centers do routine pulmonary function testing prior to decision on LVAD
candidacy. However, no established parameters exist in order to accept or not to
The VAD Journal: https://doi.org/10.13023/VAD.2018.04
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accept the patients for LVAD based on the results. When patients were stratified in
five groups by forced expiratory volume in one second and diffusing capacity for
carbon monoxide, ranging from <40% predicted to normal, there was no
association with survival and no difference in mortality at 1 and 3 years between
the groups. Only diffusing capacity of the lungs for carbon monoxide was
associated with increased intensive care unit length of stay in the group analysis
(P =0.001). Ventilator times, postoperative pneumonia, reintubation, and
tracheostomy rates were similar across the groups. These findings suggest that
abnormal pulmonary function tests alone should not exclude patients from
consideration of mechanical circulatory support (29).
Adult Congenital Disease
Adult patients with congenital heart disease are rarely supported with long-term
VADs. In the INTERMACS, 128 such patients were identified. Comparing with
propensity-matched cohort, they have longer hospital stay, higher mortality,
especially in the first 5 months after implantation, and lower probability of receiving
a transplant (p = 0.003). Risk factors for early mortality were biventricular support
with two VADs or total artificial heart device implant and age > 50 years old (30).
Survey of LVAD programs
Many programs implanting LVADs, struggle with the same questions and there is
no literature to guide decision-making. A break-through paper by Kilic et al. (31)
was published in our journal. It appeared, for example, that current practices in
candidate selection with regards to substance abuse stand as the following:
require abstinence from marijuana, but not tobacco 11%, require abstinence from
tobacco, but not marijuana 2%, require abstinence from both 42%, do not require
abstinence from either 38%, and have a don’t ask/don’t tell policy 6%.

Management of patients on LVAD support
Hemodynamic optimization
In the past issues of this annual review, we extensively covered the topic of
incomplete hemodynamic compensation and residual LV failure after LVAD
implantation. In 2017, new evidence was presented showing that right heart
catheterization three months after the LVAD implantation was abnormal, with
decreased cardiac index or elevated pulmonary capillary wedge pressure or both
in almost 30% of the patients. With ramp test, normalization of hemodynamics was
achieved in 68% patients with initially abnormal hemodynamics. This resulted not
only in better hemodynamic parameters but in increase in 6 minute walk distance
(32).
The same concept, some degree of HF on LVAD, is indirectly proven by high
prevalence and doses of loop diuretic use after LVAD implantation. Almost all
patients, 95%, require loop diuretics before the LVAD. Although this proportion
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decreases after the implant and remains below this level for two years of follow-up,
more than half of patients were on loop diuretics even 2 years after LVAD
implantation (33).
There is a growing interest to remote invasive hemodynamic monitoring with
Cardiomems (Abbott, Abbott Park, IL) in LVAD population. Our experience has
been published in the Journal before (34, 35). In 2017, data were published on 27
patients from the CHAMPION (CardioMEMS Heart sensor Allows for Monitoirng of
Pressures to Improve Outcomes in NYHA Class III heart failure patients) trial, who
required LVAD while the study was in progress. There was a trend toward a
shorter length of time to LVAD implantation in the treatment group
where hemodynamic information was available to physicians than in the control
arm where medical management was guided by clinical information only. After
LVAD implantation, decline in pulmonary artery pressure was also greater in
patients with Cardiomems (36).
Cardiomems may also be helpful in management of patients with total artificial
heart (37, 38).
.
Mechanical device failure
As patients live longer with LVAD, mechanical device failure or hardware issues
such as driveline fracture or damage, or problems with inflow and outflow graft,
electrical power, drive unit, or motor become more common, and sometimes fatal.
In a single center, such failure occurred in 13% of patients on HM2 at a median
time of about three years after implantation, increasing from 0% in the first year to
36% in the third. Longer time on pump predisposed to hardware failure. Driveline
fracture was by far the commonest problem (89%) (39).
Other series report much lower incidence of driveline fracture at 3.2%. Although
some cases of driveline fracture required device exchange, the majority of cases
(88%) were fixed with driveline repair which was durable with no related fatalities
(40). We reported the University of Kentucky experience with almost 12% of
patients having driveline complications, mostly with external fractures or injuries,
and with high mortality rate (41).
In the most detailed report, including both HM2 and HeartWare LVADs, types of
device malfunction included controller failure (30%), battery failure (19%), driveline
failure (14%), or pump failure (13%) and were more common in HM2 (3.73 per
1000 patient-days versus 3.06 per 1000 patient-days for the Heartware, P<0.01).
Patients with HVAD were 90% free of a pump-specific malfunction at 3 years
compared with 56% for the HM2 (log-rank P<0.003). Only 74% of the patients with
HM2 were free of pump thrombosis at 3 years compared with 90% of the patients
with HVAD. Freedom from failure of the integrated driveline was 79% at 3 years for
the HM2 but 100% for the HVAD (log-rank P<0.02) (42).
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Obesity
Laparoscopic sleeve gastrectomy was reported again last year as an option for
patients who want to have cardiac transplantation after LVAD implant (43), adding
to already existing literature (44). After driveline mapping by ultrasound or
fluoroscopy, bariatric surgery was successfully performed in three patients. All
achieved sufficient weight loss to be listed and two were transplanted.
CPR in VAD
Cardiac arrest in a patient with LVAD is one of the most challenging situations in
management of this population. In 2017, the most comprehensive document
covering this topic, a scientific statement from the American Heart Association,
was published (45). This and other algorithms are discussed in detail in the current
volume of the Journal (46).
Arrhythmias
It is well known that ventricular arrhythmias are much better tolerated on LVAD
support, sometimes to the degree that ventricular fibrillation is discovered
incidentally, in alert patients with normal end organ function and mild symptoms
(47). The role of implantable cardioverters-defibrillators (ICDs) remains
controversial.
The INTERMACS analysis performed with propensity matching in order to
generate similar cohorts, one with ICD and another without, included over 2000
patients per arm. The presence of an ICD was associated with an increased
mortality risk (HR 1.20; 95% CI 1.04 to 1.39; p = 0.013) and an increased risk of
unexpected death on device support (HR: 1.33; 95% CI: 1.03 to 1.71;
p = 0.03). Patients with an ICD were more likely to undergo transplantation (HR:
1.16; 95% CI: 0.99 to 1.35; p = 0.06) and less likely to have LVAD explant for
recovery (HR: 0.53, 95% CI: 0.29 to 0.98; p = 0.04). They also had higher
hospitalization rates (48).
Although propensity matching is not perfect and there may be still baseline
differences, this is the largest dataset currently available and, clearly, ICDs were
not associated with any benefit.
Electrical storm in patients not on hemodynamic support is a very difficult to
manage and frequently fatal condition. Typically, the combination of antiarrhythmic
drugs and ECMO for hemodynamic stability is used with or without ablation
attempts. The usual argument against LVAD is that LVAD does nothing for
ventricular tachycardia/fibrillation. One case report, published in 2017, showed that
mechanical unloading of LV, in this case by Impella, can terminate ventricular
tachycardia (49).
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Under other circumstances, LVAD may directly cause refractory ventricular
arrhythmia by tissue damage and inflammation at the inflow cannula site, which
can be treated by ablation (50).
Atrial arrhythmias in LVAD population are prevalent and occur in about half of
patients. Interestingly, patients with paroxysmal atrial fibrillation before the
implantation have less episodes on LVAD support, presumably due to
improvement in geometry and shrinking in size of the left atrium (51).
Atrial fibrillation may contribute to morbidity and mortality on LVAD or be a marker
of more severe disease. In a single center study, two year survival was 65.4% in
the sinus rhythm group and 51.3% in the atrial fibrillation group, HR 1.48, 95% CI:
1.02-2.15; p = 0.038). Also, patients in atrial fibrillation more commonly had RV
failure, but there was no difference in bleeding and thromboembolic events (52).
LVAD and Valves
Mitral valve
Almost all LVAD candidates have some degree of mitral regurgitation (MR). LVAD
unloads the LV irrespective of preoperative MR severity and results in partial
resolution of mitral insufficiency. Less than 10% of patients who had at least
moderate to severe MR before the implantation still have that degree of
regurgitation after 6 months on LVAD (53).
At the same time, patients with significant residual MR have larger RV size, worse
RV function, higher post-implantation pulmonary artery pressures, and shorter time
to re-hospitalization and death (54).
There is still no consensus on surgical correction of MR during LVAD implantation.
In the past years we cited studies revealing detrimental effects of residual, more
than mild MR(55), and advocating aggressive correction of MR (56). In 2017, the
INTERMACS analysis showed that two-year survival was 76%
for concomitant mitral valve repair, 57% for valve replacement, and 71% for no
mitral valve intervention (non-significant), but there were fewer readmissions in
patient with concomitant surgical procedures on the valve (57). Also, in the
experience of Columbia University, mitral valve repair effectively prevented RV
failure and hospital readmissions after surgery (0.03 vs 0.15 readmissions per
patient-year for repaired and non-repaired MV; P =0.011)(58). No difference in
terms of survival or admissions was found in a single center (Barcelona, Spain)
study with a trend to better outcomes in those whose valve was repaired (59) .
Aortic valve
Aortic regurgitation is very prevalent (may exceed 40%) in patients on LVAD
support and contributes to higher baseline central venous pressure, PCWP, and
lower pulmonary artery pulsatility index. While increase in LVAD speed improves
hemodynamics, it also deteriorates aortic regurgitation. The question of aortic
valve repair during the LVAD implant is being debated (60).
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As many as 12.6% of LVAD recipients were found to have baseline pre-LVAD mild
aortic insufficiency. If the valve was repaired during LVAD implantation, freedom
from moderate or severe aortic regurgitation was 81.8 ± 9.7%, versus 45.0 ± 21.1%
(P = 0.031) in patients who did not undergo the repair. The likelihood of aortic
regurgitation progression was particularly common in patients with larger aortic
roots (61).
Anticoagulation in VADs
While the need to maintain therapeutic anticoagulation on LVAD is accepted as
standard of care, the rigor of standards for daily use is still debated. The question
of bridging patients with subtherapeutic international normalization ratio (INR)
using other anticoagulants is currently unresolved. In retrospective analysis from
University of Chicago, bridging with enoxaparin resulted in a fourfold increase in
major bleeding episodes during the bridged period (2.02 vs. 0.45 events per year
in non-bridged patients; p = 0.03). There was also a trend towards higher rate of
thromboembolism in bridged patients (0.20 vs. 0.11 events per year; p = 0.08).
Average INR at the time of initiation of enoxaparin was 1.46 (62).
The discussion on whether aspirin should be a mandatory component of
management of patients on LVAD support continues. Our prior reviews included
results of both European (63) and American (64) STudy of Reduced AntiCoagulation/Anti-platelEt Therapy in Patients with the HeartMate II LVAS
(TRACE), but no prior study directly compared the incidence of bleeding and
thrombotic events between antithrombotic regimens with and without aspirin. A
single-center, retrospective analysis of patients with HM2 receiving warfarin and
aspirin 81 mg/day versus warfarin alone, showed no significant difference in
bleeding (34% versus 43%, respectively, p = 0.48) or thrombotic events (9 versus
11%, respectively, p = 1.00) (65). It might be safe to manage patients on warfarin
alone.
Given the amount of time we all spend on daily adjustment of warfarin dose, it is
very tempting to anticoagulate patients on LVADs support with direct thrombin
inhibitors. The first attempt was made and failed. Thirty patients on HeartWare with
stable renal function were randomized to receive either phenprocoumon (vitamin K
antagonist) or dabigatran 110 or 75 mg twice a day in addition to aspirin. The trial
was stopped after only 16 patients because thromboembolic events occurred in
50% on dabigatran (four out of eight patients) and only in one patient (13%) on
phenprocoumon (66).
Heparin Induced Thrombocytopenia
The group from Columbia University described their protocol for LVAD
implantation in patients with heparin induced thrombocytopenia, which they used
successfully in 6 patients, four of which had confirmed heparin induced
thrombocytopenia. They give abciximab, 0.25 mg/kg loading dose, followed by
continuous infusion of 0.125 mcg/ kg/min throughout cardiopulmonary bypass.
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With abciximab infusion established, and before cardiopulmonary bypass, they
start full-dose heparin to maintain an activated clotting time of ≥ 400 s. At the end
of cardiopulmonary bypass, they reverse heparin with protamine, and stop
abciximab 15 minutes after heparin reversal. They follow with transfusion of 18-24
units of platelets, and start argatroban with transition to warfarin when drainage
from mediastinal tube became serosanguineous (67).
Noncardiac surgery
The question about management of LVAD patients, primarily in terms of
anticoagulation, around planned interventions or surgeries is poorly investigated.
In a retrospective large single center series from Duke, 32 patients with average
preoperative INR 1.76 ± 0.47 underwent extractions and minor oral surgeries. In
about 40% of anticoagulated patients warfarin was held while in the rest it was not;
there was no difference in drop of hemoglobin post procedure, and only one
patient required transfusion. Bridging with heparin was done in four patients (68).
From this experience, dental procedures are safe and may not require interruption
in anticoagulation.
LVAD and sex, driving, etc…
Decrease in quality of sexual activities was noted in over 50% of patients with
LVADs, likely contributing to high rate of depression (69).
Successful pregnancy and delivery via cesarean section was also reported,
suggesting that LVAD can adequately support increased hemodynamic needs
during pregnancy (70).
Driving habits of LVAD recipients were also reported and it appeared that majority
(70%) of patients return to driving after LVAD (71).

Complications of the VADs
Orthostatic hypotension
A newly recognized complication of chronic LVAD support was described by
investigators from Duke who reported a series of three patients with orthostatic
hypotension due to acquired autonomous dysfunction, confirmed by tilt table test.
Upright position decreases preload, resulting in a reduction in chamber size in the
setting of continuous unloading. Midodrine, fludrocortisone, compression
stockings, and diuretic restriction may alleviate the symptoms (72).
Pump thrombosis
Further contributions were made in 2017 to understanding of the genesis of pump
thrombosis. Bartoli et al. (73) reported that although lactate dehydrogenase (LDH)
remains elevated on LVAD support, plasma free hemoglobin decreases after initial
post-implant peak.
The VAD Journal: https://doi.org/10.13023/VAD.2018.04
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In patients who developed pump thrombosis, both LDH and plasma free
hemoglobin remained elevated, unlike in patients without thrombosis before (p <
0.001) and after 3 months (p < 0.05) of support. In the in vitro study, free
hemoglobin inhibited ADAMTS-13 activity during shear stress and therefore
protected von Willebrand factor from degradation. The authors concluded that
higher degree of hemolysis may create a prothrombotic state which can increase
the risk of pump thrombosis (73).
Last year, we included the results of the PREVENT (PREVENtion of HeartMate II
Pump Thrombosis Through Clinical Management) trial in our annual review. This
was a prospective, multi-center, single-arm, non-randomized study of 300 patients
with HM2. Investigators agreed on the best practices in terms of implant technique,
anti-coagulation strategy, and pump speed management. In 2017, the substudy of
268 patients included in this trial, who had two or more LDH measurements at ≥30
days post-implant, was published. Out of these patients, 14% had elevated LDH,
defined as ≥2.5× upper limit of normal for two consecutive measurements. Strokefree survival at 6 months was lower in patients with elevated than with normal LDH
(83 ± 6% vs 93 ± 2%, p = 0.035). Elevated LDH resolved without intervention in
19% of patients, with intensified medical therapy in 43% and required surgical
intervention for suspected pump thrombosis in 38%. For patients receiving only
medical therapy, including one or more of the following: intravenous heparin, lowmolecular-weight heparin, intravenous direct thrombin inhibitor, and/or new antiplatelet therapy, survival was excellent at 94 ± 6% at 6 months post-treatment,
with pump thrombosis in only one patient. The authors conclude that early medical
intervention for elevated LDH is justified (74).
Gastrointestinal Bleeding
An ongoing frustration with management of GI bleedings on LVAD results in
continuous search of new diagnostic and treatment options. It was discovered that
LVAD causes a distinct form of intestinal angiodysplasia. Patients on LVAD not
only have higher intestinal vascularity, but they also have abnormal vascular
architecture in the submucosa of the jejunum (75).
Deregulation of an angiogenic factor, angiopoietin-2, may be responsible for
increased angiogenesis. Serum levels and endothelial expression of this factor
were higher in LVAD patients than in patients with heart failure but without LVADs
or with heart transplantation (P=0.001 and P<0.001, respectively). Moreover,
LVAD patients had an elevated thrombin activation, and thrombin is known to
induce angiopoietin-2 secretion.
LVAD patients with higher angiopoietin-2 levels bled more, which led the authors
to conclusion that this factor may contribute to development of arteriovenous
malformations (76).
Angiotensin II is another factor involved in angiogenesis through the vascular
endothelial growth factor and angiopoietin-2 pathways. It appeared that
angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy
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is associated with a lower rate of GI bleeding, including arteriovenous
malformation-associated bleeding. A retrospective review from John Hopkins
hospital showed that 48% of LVAD patients not receiving either group of drugs had
GI bleeding, comparing with 24% of those receiving angiotensin-converting
enzyme ininhibitors or angiotensin receptor blockers. The odds ratio of all GI
bleeding for patients on the therapy was 0.29, 95% CI 0.12-0.72, and for
arteriovenous malformation associated bleeding it was 0.23, CI 0.07-0.71) (77).
In terms of diagnostics it appears that capsule endoscopy, traditionally utilized by
most centers when upper and lower endoscopy fails to reveal the source of
bleeding, is not helpful. At Stanford University, capsule endoscopy did not make
difference in use of double-balloon or push enteroscopy, use of thalidomide or
octreotide, 30-day outcomes, or time to re-bleeding (78). In the experience of
University of Louisville, capsule endoscopy provided diagnostic yield of 4% (79).
On the other hand, deep single balloon enteroscopy, reaching distal jejunum, as
reported from Emory, produced a diagnostic yield of 78 % with no complications
(80).
In 2017, a multicenter, retrospective analysis evaluated LVAD patients who were
discharged after GI bleeding and received secondary prophylaxis with octreotide.
Only 24% experienced a recurrent GI bleed, comparing with 43% of historic cohort
not receiving the drug; P=0.04 (81).
In the past, we cited recommended doses of experimental treatments for GI bleeds
in LVADs: Danazol (200 mg orally twice a day) (82); octreotide (100 mcg
subcutaneously twice a day in the hospital and then 20 mg depot intramuscularly
monthly) (83). Other authors report 50 mcg subcutaneously twice a day (84).
Thalidamide was given at 50mg orally twice a day with potential increase to
maximum daily dose of 200 mg, and decrease to 50 mg every other day if toxicity
develops, monitor blood count while up-titrating and try decreasing the dose when
therapeutic effect achieved (85).
This year a series of patients were treated with thalidomide 50 mg a day, which led
to termination of GI bleeding in all 11 patients, but two of them developed pump
thrombosis. (86)
Another novel treatment, suggested last year, was inhaled desmopressin acetate
150 mcg, one nasal inhalation three days per week, in a patient with recurrent GI
bleed who failed octreotide. Desmopressin is a synthetic analogue of vasopressin
and is FDA approved for control of bleeding in patients with either hemophilia A or
mild-to-moderate von Willebrand disease. This drug is administered as spray in
one nostril 3 days a week, and has a time-to-maximal concentration of
approximately 45 minutes, and a half-life of approximately 3.5 hours. This dose
has been proven to increase levels of von Willebrand factor to 150-250% of normal
shortly after administration. Potential significant adverse effects include
hyponatremia (due to its anti-diuretic effect), hypertension and acute thrombosis
(87).
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Right ventricular failure
In the INTERMACS database, 38 patients had two centrifugal pumps implanted for
biventricular support. RVAD was implanted in the RV in 59%, in the right atrium in
41%, and the site was not specified in 13%. Survival was below the outcomes
usually reported for LV support only: 68% at 6 months and 62% at 12 months, and
the complication rate was high with infection in 50%, bleeding in 44%, respiratory
failure in 31.6%, malfunction in 26.3%, and neurologic dysfunction in 26.3% of
patients (88). Nevertheless, considering dismal prognosis in RV failure, this still
appears to be a viable option.

Various pumps
Several interesting new pumps were introduced or further developed in 2017.
The NuPulseCV (NuPulseCV, Inc., Raleigh, NC). The intravascular ventricular
assist system (iVAS) is a minimally invasive, ambulatory counterpulsation system
delivered via the subclavian artery and powered by a portable driver. It has a 50cc pump, similar to an intra-aortic balloon, placed in the descending aorta (Figure
1).

Figure 1, The intravascular ventricular assist system counterpulsation
system. Reproduced from Jeevanandam et al (89), with permission
The skin interface device is an electro- mechanical and pneumatic conduit with a
chimney that allows for shuttling of air between the pump and external driver and
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communication of the captured ECG signals. An external and wearable drive unit
provides compressed air to inflate and deflate the pump .Similar to an intra-aortic
balloon pump, this device can be operated in 1:1, 1:2 and 1:3 modes, and the
amount of augmentation is adjustable. The support can be interrupted for short
periods of time and patients can ambulate while the pump is working.
This pump was tested in a prospective, non-randomized single arm feasibility trial
in patients listed for cardiac transplantation. The primary end-point was survival to
transplant or stroke-free survival at 30 days which was achieved in all implanted
patients. One patient required escalation of mechanical support and there was
one case of pericarditis and two cases of neuropathy after the pump implantation
(89).
aVAD (ReliantHeart Inc, Houston, TX), approved in Europe, is a compact, axial
flow LVAD which has speeds ranging between 6,000 and 12,000 rpm, and the flow
up to 7 L/min. The features ofnthe device include
1) real flow measurement with ultrasonic flow probe positioned around the
outflow graft
2) remote device monitoring
3) a miniaturized pump housing. It is positioned within the LV through the apex
with a 90-degree outflow elbow positioned just outside the heart but within the
pericardial space (Figure 2).
4) adjustment of pump depth within the ventricle, which allows adjustment of
pump depth to accommodate different ventricular cavity sizes and avoid suction
events.
This device was implanted to a 61-year-old woman with severe HF. Following
uneventful surgery, the patient recovered and was successfully discharged from
the hospital (90).
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Figure 2. aVAD (ReliantHeart Inc, Houston, TX). Reproduced from Schmitto et
al.(90), with permission

What is new in VA ECMO World?
This year, we are introducing a new section and hope to make it a regular part of
this review series. We will summarize what was published in 2017 on veno-arterial
ECMO, which is not a LVAD, but certainly part of mechanical circulatory support.
Cardiogenic shock and acute decompensated HF
Interestingly, in a large series including 132 patients isolated LV failure was a risk
factor for mortality, while patients with RV failure or biventricular failure had better
prognosis (91). This differs from our results, where we found no difference in
mortality between RV and LV failure (92). In our experience, patients supported
with VA ECMO due to pulmonary embolism and HF had better survival to hospital
discharge (83.3% and 54.2%, with p = 0.003 and p = 0.011, respectively) then
patients with postcardiotomy syndrome (7.7%).
In some cases, ECMO in cardiogenic shock becomes a bridge to LVAD. Patients
with INTERMACS profile 1, who had an LVAD, were analyzed based on being or
not being on the ECMO support before the LVAD. The ECMO bridge group was
generally sicker, with lower hemoglobin and prealbumin, requiring more
transfusions and vasopressors, but had better hemodynamics than patients
without ECMO as a bridge, with lower central venous pressure, PCWP, and mean
pulmonary arterial pressure. Survival at 30 days postoperative and at 1 year (77%
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vs. 88%; p = 0.6) was similar. ECMO, therefore, is a viable option to bridge very
unstable patients to LVAD (93).
Left ventricular decompression
It is known that VA ECMO in patients with failing LV can frequently cause LV
distention and pulmonary edema. A 30-day survival on ECMO with LV
decompression is better than without LV venting (55% vs. 25%, p=0.034) (94).
Some new options for LV decompression on VA ECMO were suggested in 2017.
The most interesting one uses central biventricular cannulation with LV
approached via left mini-thoracotomy, with off-pump transapical placement of
ProtekDuo cannula, with the inflow port located in the LV and the outflow port and
cannula tips situated 2–3 cm above the aortic valve. The pump was TandemHeart,
and the oxygenator was included. For RV support, inferior vena cava- superior
vena cava venous cannula was inserted via the femoral vein and connected to the
inflow of transapical cathteter. Later, the venous catheter was stitched to internal
jugular vein and the patient was able to walk. In essence, it was placement of the
central ECMO with LV decompression, allowing patient’s mobility (95).
A large review on LV unloading was published by Meani et al.(96). They divide all
methods into
1) surgical techniques
• Implant of a LV venting catheter (cannula through the right superior
pulmonary vein either in the left atrium or LV and connected with a
Y-connector to the venous line of the circuit
2) minimally invasive surgical techniques
• Cannula implanted in the LV and then tunneled through a
subxiphoidal incision to the extracorporeal side
• Cannula inserted into LV apex via left anterolateral thoracotomy
• Transdiaphragmatic approach is used
3) Percutaneous options
• Pulmonary artery drainage with a venous cannula placed into the
main pulmonary artery, connected to the venous limb
• Trans-aortic catheter venting with pigtail inserted directly across the
aortic valve from femoral artery, connected to the venous limb
• Pediatric cannula placed into the LV through the aortic valve and
connected to the femoral arterial line
• Blade or balloon septostomy
• Transseptal left atrial drain connected to the venous limb
Indirect venting includes increasing forward flow with intra-aortic balloon pump,
TandemHeart, or Impella (96).
Electrical storm
Another indication for VA ECMO is incessant ventricular tachycardia (VT) or
electrical storm. Patients may need ECMO to provide hemodynamic stability,
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although it does not help ventricular arrhythmia per se. Besides, ventricular
stunning due to multiple shocks by defibrillator may temporarily compromise LV to
the degree of circulatory shock.
ECMO provides an opportunity to perform VT ablation or to suppress
VT/ventricular fibrillation by antiarrhythmics. A series of 21 patients in electrical
storm on ECMO support was reported by Enriquez et al. (97). Mortality was high
with 16 patients (66%) being dead in a median of 10 days, but the remaining
survived arrhythmia free.
Cardiopulmonary resuscitation
A systematic review and meta-analysis of ECMO in out-of-hospital cardiac arrest,
summarizing 15 studies with a total of 841 patients, reported following predictors
of survival: initial shockable cardiac rhythm, shorter low-flow duration, higher
arterial pH, and lower serum lactate (98).
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